Sun Pharma shares plunge as its much touted psoriasis drug trial fails
The company said in a statement on Tuesday that it is discontinuing further development of its investigational drug SCD-044, a novel orally bioavailable anti-psoriasis drug following disappointing Phase 2 trial results. This investigational drug was tested for both psoriasis and atopic dermatitis indications.
The company said that the trials (double-blind, placebo-controlled Phase 2 trial evaluated the efficacy and safety) were conducted in 263 patients with moderate to severe plaque psoriasis. The primary endpoint was the proportion of patients achieving a 75% reduction in the psoriasis area. The trial failed to meet this endpoint, although no major safety or tolerability issues were reported.
'While we are disappointed with the top-line results of the clinical trials, we would like to thank all the psoriasis and atopic dermatitis patients, the healthcare professionals and administrators who participated in these pivotal clinical trials,' said Dr. Marek Honczarenko, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 hours ago
- Time of India
Sickle cell patients await BMT as govt scheme, centres yet to take off in Nagpur
1 2 Nagpur: At least 12 sickle cell and thalassaemia paediatric patients are now endlessly waiting for bone marrow transplants (BMT) as govt-run hospitals in the region don't have a dedicated unit for them. Two government centres have been proposed, but the lack of a financial assistance scheme has only meant that the costly BMT remains a non-starter. The tertiary care centres proposed to start a dedicated BMT centre for SCD and thalassaemia patients last year with much fanfare, but there has been little progress. Similarly, a government hospital has already started a BMT centre for other blood disorders, but a dedicated unit for SCD and thalassaemia patients is still a far cry, despite it signing an MoU for funding too. City MP and Union minister Nitin Gadkari has often slammed premier institutes for dragging their feet on starting BMT for SCD and thalassaemia patients in Nagpur. Dr Sanjay Deshmukh, in charge of state-run Daga Memorial Hospital, said they registered 12 patients after screening them for HLA (Human Leukocyte Antigen) typing tests. "Before BMT, HLA typing is a must to match a donor," he said. Daga Memorial Hospital has been facilitating the HLA test in association with Sankalp Foundation for free of cost. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Could This NEW Collagen Blend Finally Reduce Your Cellulite? Vitauthority Learn More Undo The test costs Rs30,000 in a private setup. On August 18, Daga Hospital will again hold a camp for patients below 18 years with sickle cell and thalassaemia. The earlier the BMT is done, the higher the chances of its success. The samples are sent to Bangalore. WCL is funding Rs 12 lakh for BMT of SCD and thalassaemia patients in some hospitals, including one in Mumbai. The Maharashtra government is yet to offer any funding for sickle cell and thalassaemia patients for BMT. Other states offer Rs 15 to 20 lakh to these patients for BMT. A couple of private hospitals in Nagpur have done BMT for patients funded by their respective state governments. The CSR sponsors require at least an 8-bed dedicated unit to pledge funding. Vinky Rughwani, president, thalassaemia and Sickle Cell Society of India, said, "We will ensure that these 12 patients get BMT done in Mumbai, Ahmedabad, or Chennai at no cost till Nagpur gets a centre. We have taken the initiative to establish a dedicated BMT centre for these patients. We hope to see BMT done in Nagpur soon." Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Time of India
3 days ago
- Time of India
Sun Pharma Share Price Live Updates: Sun Pharma's Stock Performance This Week
Welcome to the Sun Pharma Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent stock. Dive into the current details of Sun Pharma, including: Last traded price 1641.4, Market capitalization: 393826.84, Volume: 1738094, Price-to-earnings ratio 37.97, Earnings per share 43.23. Our liveblog offers a complete overview of Sun Pharma through a blend of fundamental and technical indicators. Stay informed about breaking news that can shape Sun Pharma's performance in the market. Our market analysis and expert opinions empower you to make informed investment decisions. Join us as we unravel the potential of Sun Pharma in the ever-changing market landscape. The data points are updated as on 09:23:02 AM IST, 15 Aug 2025 Show more Show less
Hans India
6 days ago
- Hans India
Sickle Cell elimination mission tackling genetic disorder to ensure equity, dignity: PMO
New Delhi: The National Sickle Cell Anaemia Elimination Mission (NSCAEM) is aimed at tackling the genetic disorder to ensure equity and dignity to the people affected, the Prime Minister's Office said on Tuesday. In a post shared on the social media platform X, the PMO lauded a media article by Union Minister Jagat Prakash Nadda on NSCAEM, aiming for a Sickle Cell Disease-free India by 2047. 'From tackling a genetic disorder to ensuring equity and dignity, India's National Sickle Cell Anaemia Elimination Mission marks a new era in public health,' the PMO India posted on the social media platform X. Sickle Cell Disease is a chronic, single-gene disorder that causes a debilitating systemic syndrome characterised by chronic anaemia, acute painful episodes, organ infarction, and chronic organ damage, significantly reducing life expectancy. The genetic blood disorder affects the entire life of the patient, as it leads to various severe health complications. 'India's fight against sickle cell anaemia is not just about addressing a genetic disorder, it is a commitment to equity, dignity and the health of our nation's most marginalised communities,' Nadda shared on X. Calling NSCAEM a 'landmark initiative', the Union Health Minister said it not only aims 'to stop the transmission of sickle cell disease but also to restore dignity and health to millions living with this condition'. To eliminate the disease, the NSCAEM was launched by Prime Minister Narendra Modi in July 2023. The mission aims to eliminate sickle cell disease as a public health problem in India before 2047 by universal screening of 7 crore individuals aged 0-40 years in affected tribal areas by FY 2025-26. 'As India moves with determination towards the 2047 goal of eliminating SCD, the NSCAEM stands as a beacon of hope, showing what can be achieved when the government, healthcare professionals, and communities work together for a common cause,' Nadda said. Nadda's article highlighted the government's initiatives from mass screening and early diagnosis to awareness campaigns and improved treatment access with a focus on tribal communities most affected. Earlier this month, Nadda informed the Parliament that more than 6 crore people have been screened for sickle cell anaemia in the country. Of this, 2.16 lakh have been identified as diseased. He noted that the screenings under the mission were conducted in 17 states. Meanwhile, the Indian Council of Medical Research (ICMR) in a post on X shared how its low-cost Point-of-Contact device is enabling wider screening of Sickle Cell patients. 'Validation of a low-cost PoC device for #SickleCellAnaemia screening cut the price from Rs 100 to Rs 28, enabling wider reach in tribal areas. Proud to contribute to advancing India's commitment to health equity,' the ICMR posted on X.
